Lead Product(s) : BI 1584862
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Starts Phase II Trial of Oral Compound for Geographic Atrophy
Details : BI 1584862, a phospholipid modulator developed by Boehringer Ingelheim, is an investigational compound with the potential to be a first-in-class oral treatment for Geographic Atrophy.
Product Name : BI 1584862
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2025
Lead Product(s) : BI 1584862
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 764524
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Reports Positive Results in First Study for Diabetic Macular Ischemia
Details : BI 764524 is a humanized anti-Sema3A antibody intended to re-vascularize ischemic areas and reduce leakage in the retina, offering the potential to address retinal non-perfusion in retinal diseases.
Product Name : BI 764524
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 05, 2024
Lead Product(s) : BI 764524
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 1467335
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Pharmaxis
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Discontinues Development of BI 467335 for Diabetic Retinopathy
Details : Boehringer Ingelheim decided not to further develop BI 1467335 in this indication based on the lack of a clear efficacy signal and risk of dose dependent drug interactions of the compound in NPDR patients identified in another Phase I study.
Product Name : BI 1467335
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2020
Lead Product(s) : BI 1467335
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Pharmaxis
Deal Size : Inapplicable
Deal Type : Inapplicable